News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
727,978 Results
Type
Article (43227)
Company Profile (269)
Press Release (684472)
Multimedia
Podcasts (81)
Webinars (17)
Section
Business (205880)
Career Advice (2198)
Deals (35687)
Drug Delivery (114)
Drug Development (82034)
Employer Resources (175)
FDA (16574)
Job Trends (15080)
News (348755)
Policy (33051)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2662)
Accelerated approval (31)
Adcomms (26)
Allergies (139)
Alliances (50112)
ALS (169)
Alzheimer's disease (1673)
Antibody-drug conjugate (ADC) (307)
Approvals (16830)
Artificial intelligence (508)
Autoimmune disease (144)
Automation (37)
Bankruptcy (365)
Best Places to Work (11744)
BIOSECURE Act (20)
Biosimilars (189)
Biotechnology (176)
Bladder cancer (157)
Brain cancer (55)
Breast cancer (632)
Cancer (4773)
Cardiovascular disease (400)
Career advice (1853)
Career pathing (35)
CAR-T (276)
CDC (46)
Celiac Disease (2)
Cell therapy (736)
Cervical cancer (36)
Clinical research (69904)
Collaboration (1680)
Company closure (4)
Compensation (1142)
Complete response letters (56)
COVID-19 (2779)
CRISPR (90)
C-suite (811)
Cystic fibrosis (145)
Data (6156)
Decentralized trials (2)
Denatured (26)
Depression (133)
Diabetes (501)
Diagnostics (6731)
Digital health (44)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (242)
Drug pricing (190)
Drug shortages (29)
Duchenne muscular dystrophy (228)
Earnings (90149)
Editorial (55)
Employer branding (22)
Employer resources (153)
Events (117762)
Executive appointments (959)
FDA (19654)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (23)
Funding (1458)
Gene editing (195)
Generative AI (42)
Gene therapy (591)
GLP-1 (982)
Government (4725)
Grass and pollen (7)
Guidances (384)
Healthcare (19111)
HIV (55)
Huntington's disease (45)
IgA nephropathy (81)
Immunology and inflammation (249)
Immuno-oncology (54)
Indications (103)
Infectious disease (3039)
Inflammatory bowel disease (187)
Inflation Reduction Act (14)
Influenza (110)
Intellectual property (242)
Interviews (367)
IPO (16681)
IRA (49)
Job creations (3673)
Job search strategy (1547)
JPM (57)
Kidney cancer (15)
Labor market (83)
Layoffs (561)
Leadership (30)
Legal (8021)
Liver cancer (92)
Longevity (14)
Lung cancer (641)
Lymphoma (371)
Machine learning (42)
Management (59)
Manufacturing (781)
MASH (161)
Medical device (13908)
Medtech (13961)
Mergers & acquisitions (20060)
Metabolic disorders (1267)
Multiple sclerosis (157)
NASH (16)
Neurodegenerative disease (309)
Neuropsychiatric disorders (88)
Neuroscience (2894)
Neurotech (1)
NextGen: Class of 2026 (6619)
Non-profit (4586)
Now hiring (65)
Obesity (595)
Opinion (268)
Ovarian cancer (164)
Pain (200)
Pancreatic cancer (225)
Parkinson's disease (282)
Partnered (33)
Patents (488)
Patient recruitment (470)
Peanut (56)
People (59154)
Pharmaceutical (62)
Pharmacy benefit managers (29)
Phase 1 (21810)
Phase 2 (30760)
Phase 3 (22924)
Pipeline (5082)
Policy (285)
Postmarket research (2593)
Preclinical (9295)
Press Release (67)
Prostate cancer (234)
Psychedelics (50)
Radiopharmaceuticals (279)
Rare diseases (825)
Real estate (6016)
Recruiting (70)
Regulatory (24632)
Reports (51)
Research institute (2465)
Resumes & cover letters (367)
Rett syndrome (27)
RNA editing (17)
RSV (77)
Schizophrenia (147)
Series A (241)
Series B (189)
Service/supplier (11)
Sickle cell disease (98)
Special edition (21)
Spinal muscular atrophy (160)
Sponsored (42)
Startups (3677)
State (2)
Stomach cancer (17)
Supply chain (106)
Tariffs (86)
The Weekly (53)
Vaccines (1011)
Venture capital (88)
Weight loss (388)
Women's health (87)
Worklife (18)
Date
Last 7 days (594)
Last 30 days (2094)
Last 365 days (29851)
2026 (2821)
2025 (30300)
2024 (35386)
2023 (40272)
2022 (51459)
2021 (56059)
2020 (54563)
2019 (47102)
2018 (35518)
2017 (32460)
2016 (31886)
2015 (37969)
2014 (31691)
2013 (26697)
2012 (28931)
2011 (29610)
2010 (27622)
Location
Africa (765)
Alabama (83)
Alaska (7)
Arizona (305)
Arkansas (13)
Asia (39665)
Australia (6562)
California (11169)
Canada (3253)
China (1084)
Colorado (472)
Connecticut (470)
Delaware (333)
Europe (86423)
Florida (1663)
Georgia (357)
Hawaii (3)
Idaho (62)
Illinois (857)
India (62)
Indiana (516)
Iowa (22)
Japan (418)
Kansas (126)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1373)
Massachusetts (7995)
Michigan (319)
Minnesota (626)
Mississippi (5)
Missouri (125)
Montana (31)
Nebraska (28)
Nevada (122)
New Hampshire (78)
New Jersey (2988)
New Mexico (29)
New York (2951)
North Carolina (1436)
North Dakota (8)
Northern California (5442)
Ohio (329)
Oklahoma (21)
Oregon (42)
Pennsylvania (2254)
Puerto Rico (22)
Rhode Island (49)
South America (1135)
South Carolina (65)
South Dakota (1)
Southern California (4345)
Tennessee (172)
Texas (1721)
United States (39634)
Utah (336)
Vermont (1)
Virginia (258)
Washington D.C. (81)
Washington State (913)
West Virginia (4)
Wisconsin (106)
Wyoming (2)
727,978 Results for "abl inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
December 29, 2025
·
2 min read
Press Releases
Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting
December 8, 2025
·
4 min read
Neuroscience
GSK Dives Deeper Into Neuro With $2.5B+ ABL Bio Pact
GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.
April 7, 2025
·
2 min read
·
Tristan Manalac
Business
Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates
Biocytogen Pharmaceuticals and ABL Bio Inc. today announced a collaboration to develop new bispecific antibody-drug conjugates (bsADCs).
March 25, 2024
·
4 min read
Press Releases
ABLi Therapeutics Completes Collaboration Agreement with The Michael J. Fox Foundation to include Risvodetinib in Path to Prevention Platform Trial
January 28, 2026
·
4 min read
Press Releases
ABLi Therapeutics Launches with a Focus on Developing Treatments for Neurodegenerative Diseases that Arise from Activation of c-Abl Kinases
May 12, 2025
·
4 min read
Genetown
Ablative Solutions, Inc. Announces Primary Endpoint Met in the TARGET BP I Pivotal Trial of the Peregrine System™ Kit for Patients with Uncontrolled Hypertension
Ablative Solutions, Inc., today announced that the TARGET BP I Pivotal Trial evaluating alcohol-mediated renal denervation with the Peregrine System ™ Kit met its primary endpoint, showing a statistically significant difference in 24-hour Ambulatory Blood Pressure between treatment and sham procedure at 3 months.
December 19, 2023
·
2 min read
Deals
Oxford Biomedica completes acquisition of ABL Europe
Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces that, following the announcements on 20 September and 4 December 2023, it has today completed the acquisition of ABL Europe SAS (“ABL Europe”) from Institut Mérieux SA (“Institut Mérieux”).
January 29, 2024
·
4 min read
Press Releases
60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio
January 16, 2026
·
6 min read
Government
US Government Shuts Down, FDA Closed for New Applications
Due to policies regarding industry user fees, the FDA will not be able to accept any new drug applications for the duration of the government shutdown, according to Leerink Partners.
October 1, 2025
·
4 min read
·
Annalee Armstrong
1 of 72,798
Next
